How Temple University Health System posted an $89M profit in fiscal 2020 despite Covid-19
Fueled by a strong performance at its flagship hospital, Temple University Health System posted an $88.8 million profit in fiscal 2020 despite the Covid-19 challenges in the last quarter. The North Philadelphia health system generated revenue of just under $2.3 billion in the fiscal year ending June 30. The health system's revenue and net income are both up from the previous year's figures of $2.25 billion and $24.95 million, respectively. "Fiscal year 2020 was an extraordinary y ear for Temple… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 25, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

How Temple University Health System posted an $89M profit in fiscal 2020 despite Covid-19
Fueled by a strong performance at its flagship hospital, Temple University Health System posted an $88.8 million profit in fiscal 2020 despite the Covid-19 challenges in the last quarter. The North Philadelphia health system generated revenue of just under $2.3 billion in the fiscal year ending June 30. The health system's revenue and net income are both up from the previous year's figures of $2.25 billion and $24.95 million, respectively. "Fiscal year 2020 was an extraordinary y ear for Temple… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 25, 2020 Category: Biotechnology Authors: John George Source Type: news

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online i...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

The Debt the Government Does Not Want to Recognize
By Saul Escobar ToledoMEXICO CITY, Sep 11 2020 (IPS) The national occupation and employment survey prepared by INEGI, with figures updated to July 2020, shows an improvement that has occurred in the last two months. However, the employment situation, compared with the data existing before the pandemic still shows serious problems: Saul Escobar ToledoOf the 12 million who left the labor market since the beginning of April, 7.2 have already returned; the other 4,800,000 declared they needed a job, but they are not looking for one. In addition, another important portion of the workforce became part of the people characterize...
Source: IPS Inter Press Service - Health - September 11, 2020 Category: International Medicine & Public Health Authors: Saul Escobar Toledo Tags: Development & Aid Economy & Trade Headlines Health Humanitarian Emergencies Labour Latin America & the Caribbean TerraViva United Nations Source Type: news

Sectra's orders increase, profit does not
PACS vendor Sectra saw a jump in order bookings for the first quarter of its...Read more on AuntMinnie.comRelated Reading: Sectra secures contract in Michigan Sectra inks deal with Christus Health Sectra wins enterprise imaging deal in Canada Sectra inks 5-year contract with Mo. health network Sectra releases 6-month financial results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 4, 2020 Category: Radiology Source Type: news

Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson &...
Source: Johnson and Johnson - September 3, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Advocate Aurora cites Covid-19 impact for $217M quarterly loss
Advocate Aurora Health CEO Jim Skogsbergh has referred to Covid-19 as causing a “financial disaster” for health care systems, and his organization proved that by posting a $217 million operating loss in its most recent quarter. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 31, 2020 Category: Pharmaceuticals Authors: Rich Kirchen Source Type: news

Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate
MONTRÉAL, QC - August 31, 2020 - Janssen Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has agreed in principle to supply the Government of Canada with doses of its SARS-CoV-2 vaccine candidate, Ad26.COV2.S. The availability of the vaccine candidate is subject to its successful development and Health Canada regulatory approval. “We are deeply committed to providing global access to our SARS-CoV-2 vaccine candidate. As we proceed with development of our vaccine, we are simultaneously working with partners around the world, including the Government of Canada...
Source: Johnson and Johnson - August 31, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Mayo Clinic turned profit in Q2 as many health providers lost big money
The Mayo Clinic on Thursday reported second-quarter operating income of $154 million, only half the operating income the health provider had in the same period last year. But most health systems lost money during the same period as pandemic lockdowns forced clinics to close and hospitals to delay non-essential procedures and tests. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 21, 2020 Category: Pharmaceuticals Authors: Carrigan Miller Source Type: news

Mayo Clinic turned profit in Q2 as many health providers lost big money
The Mayo Clinic on Thursday reported second-quarter operating income of $154 million, only half the operating income the health provider had in the same period last year. But most health systems lost money during the same period as pandemic lockdowns forced clinics to close and hospitals to delay non-essential procedures and tests. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 21, 2020 Category: Biotechnology Authors: Carrigan Miller Source Type: news

Sutter Health financials turn around in second quarter, with $231 million in income
Sutter Health's financial performance improved in the second quarter, with the Sacramento-based health system reporting $231 million in net income. The result compares with net income of $134 million in the year-earlier quarter, Sutter said in a disclosure to bondholders on Wednesday. The improved second-quarter performance also came after Sutter reported a loss of $1.08 billion in the first quarter of this year, when the Covid-19 pandemic be gan to spread across California. In the first quarter,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2020 Category: Biotechnology Authors: Felicia Alvarez Source Type: news

Sutter Health financials turn around in second quarter, with $231 million in income
Sutter Health's financial performance improved in the second quarter, with the Sacramento-based health system reporting $231 million in net income. The result compares with net income of $134 million in the year-earlier quarter, Sutter said in a disclosure to bondholders on Wednesday. The improved second-quarter performance also came after Sutter reported a loss of $1.08 billion in the first quarter of this year, when the Covid-19 pandemic be gan to spread across California. In the first quarter,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 20, 2020 Category: Pharmaceuticals Authors: Felicia Alvarez Source Type: news

Give  disabled people the right to work from home after Covid-19, says UNISON    
  Disabled employees work​ing from home during lockdown say they​ have been more productive and took fewer days off sick than when ​they were doing their job​s in the office, according to a survey published today (Wednesday) by UNISON. The union is now calling on the government to give disabled people a new right to work from home if they w​ish and for employers to face penalties if they do​n’t comply. Disabled employees should have the right under equality laws* to ‘reasonable adjustments’ ...
Source: UNISON Health care news - August 19, 2020 Category: UK Health Authors: Sophie Goodchild Tags: News Press release disability home working guide Source Type: news

Baptist Health revenue dips 23% as fewer patients visit clinics, emergency rooms
Patient care revenue dropped 23% at Baptist Health South Florida during the quarter ended June 30 as the Covid-19 pandemic kept many patients from seeking care. The Miami-based nonprofit suffered an operating loss during the quarter, but still generated a profit from investment gains. Baptist Health had an operating loss of $464,000, compared to an operating profit of $128 million in the same quarter a year ago. The company's revenue declined because of fewer patient visits to outpatient clinics… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 17, 2020 Category: Biotechnology Authors: Brian Bandell Source Type: news

South Africa: Citizens Hungry for Change but No Appetite for Loss
[New Frame] Voters and citizen movements pressing for justice in South Africa are in a better position than they have been for a quarter century, so why are they not acting on this strength? (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 17, 2020 Category: African Health Source Type: news

Atrium Health continues to battle the economic fallout from Covid-19
Atrium Health is still weathering the financial impact from Covid-19. It saw a $312.65 million net loss in the first half of 2020. Much of that is due to changes in the fair value of investments, which has dropped by more than half compared to the first two quarters of 2019. Atrium posted $698.2 million in net income in the first half of 2019. Atrium had initiall y budgeted for $289.17 million in net income in the first six months, including $107.72 million in operating income. The Charlotte-based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 13, 2020 Category: Biotechnology Authors: Caroline Hudson Source Type: news

Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results. For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Health - August 13, 2020 Category: Consumer Health News Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news

Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results. For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Science - August 13, 2020 Category: Science Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news

Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis
Basel, 10 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced topline results from its phase III study programme evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumour ...
Source: Roche Media News - August 10, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis
Basel, 10 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced topline results from its phase III study programme evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumour ...
Source: Roche Investor Update - August 10, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
New Brunswick, N.J., August 05, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of th...
Source: Johnson and Johnson - August 5, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

04.08.20: Second quarter of 2020:
Bayer: Solid performance despite COVID-19 impactEnsuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations - agreements in m...
Source: Bayer IR Newsfeed: Events - August 4, 2020 Category: Pharmaceuticals Source Type: news

Address Malnutrition with Food Insecurity
By Jomo Kwame SundaramKUALA LUMPUR, Malaysia, Aug 4 2020 (IPS) The 2020 State of Food Security and Nutrition in the World, issued by the Food and Agriculture Organization and its United Nations partners in mid-July, reports that chronic hunger continued to increase to 690 million worldwide in 2019, 60 million more than in 2014. Jomo Kwame SundaramSome two billion people worldwide were already experiencing some food insecurity during 2019, a number likely to spike upward due to Covid-19. Although headline hunger numbers have been significantly revised down retrospectively with better official data, the uptrend remains alar...
Source: IPS Inter Press Service - Health - August 4, 2020 Category: International Medicine & Public Health Authors: Jomo Kwame Sundaram Tags: Africa Development & Aid Economy & Trade Food & Agriculture Food Security and Nutrition Food Sustainability Global Green Economy Headlines Health TerraViva United Nations Source Type: news

Bayer: Solid performance despite COVID-19 impact
Ensuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx& portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx& portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations– agreements in major legacy Monsanto litigation / Core earnin...
Source: Bayer Company News - August 4, 2020 Category: Pharmaceuticals Source Type: news

Cerner ’s second quarter: a ‘burst of innovation’ (and a $35M acquisition)
Cerner Corp. ’s second quarter saw a 6% jump in profit on a 7% drop in revenue, leaving CEO Brent Shafer pleased “given the unique, unexpected circumstances.” Profits rose to $134.7 million with revenue falling to $1.33 billion. But CFO Marc Naughton said during an earnings call that the revenue results h ad little effect on profits because declines came primarily in low-margin areas, such as technology resale and travel, Fierce Healthcare reports. Shafer pointed to the North Kansas City-based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 31, 2020 Category: Biotechnology Source Type: news

Encompass Health posts lower 2Q profit, but patient volumes rebounding
Profits declined at Encompass Health Corp. in the second quarter, compared to a year ago, but the company said businesses has accelerated after hitting a low point in April due to the pandemic. The company posted $49.3 million in net income in the second quarter, which was down from $110.9 million a year ago as the company, like many other health providers, saw a decline in patient volumes due to the pandemic. “Our patient volumes in both business segments have substantially rebounde d from the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 30, 2020 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Cigna Profits Rise As Patients Delay Treatment In Pandemic
Cigna is the latest health insurer to report a big boost in second-quarter profits as its health plan members postpone treatment during the spread of the Coronavirus strain Covid-19. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 30, 2020 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Consumer Tech /consumer-tech Editors' Pick editors-pick business pharma Source Type: news

Anthem Blue Cross Profits Soar As Patients Postpone Care In Pandemic
Anthem ’s profits doubled to more than $2 billion in the second quarter as elective procedures the large health insurer pays for delayed amid the spread of the Coronavirus strain Covid-19. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 29, 2020 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Enterprise Tech /enterprise-tech Editors' Pick editors-pick Coronavirus business pharma Source Type: news

Pandemic hurts sales, profit for Pfizer amid restructuring
Drugmaker Pfizer on Tuesday reported a 32% plunge in second-quarter profit, as the global coronavirus pandemic limited marketing of new prescriptions for its medicines (Source: ABC News: Health)
Source: ABC News: Health - July 28, 2020 Category: Consumer Health News Tags: Health Source Type: news

HCA Healthcare Posts Surprise Profit as Elective Surgery Demand Improves HCA Healthcare Posts Surprise Profit as Elective Surgery Demand Improves
HCA Healthcare reported a surprise quarterly profit on Wednesday, as the US hospital operator saw a gradual pickup in demand for elective surgeries.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 23, 2020 Category: Surgery Tags: Business of Medicine News Source Type: news

Covid-19 Compounds Developing Country Debt Burdens
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Jul 23 2020 (IPS) Covid-19 is expected to take a heavy human and economic toll on developing countries, not only because of contagion in the face of weak health systems, but also containment measures which have precipitated recessions, destroying and diminishing the livelihoods of many. Limited fiscal space Developing countries generally have limited fiscal capacities to finance relief and liquidity provision in the short-term while rebuilding economic life on a more sustainable basis in the longer-term. Anis Chowdhury The 2020 Financing for Sustainable De...
Source: IPS Inter Press Service - Health - July 23, 2020 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Development & Aid Economy & Trade Featured Financial Crisis Global Headlines Health Humanitarian Emergencies TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?
While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even w...
Source: TIME: Health - July 21, 2020 Category: Consumer Health News Authors: Alejandro de la Garza Tags: Uncategorized UnitedWeRise20Disaster Source Type: news

South Africa: SAA Reveals Lockdown Financial Loss
[Daily Maverick] SAA has recorded a net loss of R1.97bn for quarter one of its 2020 financial year, which covers the three months from April to June. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 20, 2020 Category: African Health Source Type: news

Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Click to Access Audio Press ReleaseRARITAN, NJ, July 17, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today six-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of the investigational adeno-associated virus retinitis pigmentosa GTPase regulator (AAV-RPGR) were generally well-tolerated and indicated significant improvement in vision. Initial data on the novel AAV-RPGR asset, jointly developed with Meir...
Source: Johnson and Johnson - July 17, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

UnitedHealth Group Doubles Profits As Patients Defer Care In Pandemic
UnitedHealth Group profits doubled to $6.6 billion in the second quarter as elective procedures the large health insurer pays for were postponed during amid the spread of Covid-19. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 15, 2020 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Consumer Tech /consumer-tech Editors' Pick editors-pick Coronavirus business pharma Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Donald Trump, Working Class Hero?
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Jul 7 2020 (IPS) In his early February annual State of the Union address, US President Donald Trump typically hailed his own policies for increasing wages and jobs to achieve record low US unemployment. Directly appealing to labour for a second term, Trump claimed exclusive credit for the US “blue-collar boom”. Anis Chowdhury ‘Blue-collar boom’ During his previous two State of the Union speeches, Trump also directly appealed to blue-collar Americans who put him in the White House in November 2016. As Trump claims manufacturing worke...
Source: IPS Inter Press Service - Health - July 7, 2020 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Economy & Trade Featured Financial Crisis Headlines Health Humanitarian Emergencies Inequity Labour North America TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rite Aid ’s Coronavirus Safety Costs Overshadow Big Jump In Sales
Rite Aid saw a big jump in overall sales as cases of the coronavirus strain Covid-19 surged this spring, but costs of protecting employees and customers hit profits in the drugstore chain ’s first quarter, the company said Thursday. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 25, 2020 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Retail /retail Editors' Pick editors-pick Coronavirus pharma Source Type: news

Despite losses, one local hospital managed its way to operating gain in the quarter
But that doesn't mean that everything was rosy: The hospital saw sharp drops in net patient revenue and a big investment loss in the quarter because of the Covid-19 global pandemic. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 18, 2020 Category: Biotechnology Authors: Paul J. Gough Source Type: news

‘I Have the Skills, I Have the Training.’ How Refugee Doctors Are Helping the U.S. Fight COVID-19 Even Without a Medical License
Long before he started medical school in Baghdad, Ahmed Al-Sarray knew he wanted to make a difference in people’s lives. By the time he graduated in 2015, that search for purpose evolved into a passion for health care in times of crisis. Even a grueling medical residency in the hardest-hit emergency rooms and trauma wards of Baghdad’s war-torn hospitals wasn’t enough to deter him. But the militants were. As rival militias flooded Al-Sarray’s emergency ward starting in 2017, he found himself fighting for his own life as much as those of his patients. Militia leaders demanded that he care for their fi...
Source: TIME: Health - June 9, 2020 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized COVID-19 UnitedWeRise20Monthly Source Type: news

Coronavirus Vaccine: Here Are The Latest Developments
(CNN) — While coronavirus keeps spreading and killing with impunity, the world waits for a vaccine that could quash the pandemic. But details and timelines keep shifting. Here’s the latest on where we stand in the race for a vaccine: When will a Covid-19 vaccine be available to the public? No one’s sure yet, but the target is sometime in early 2021. Vaccines in development around the world are in various stages of testing. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he’s confident one of the vaccine candidates will be proven safe and effective by th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 8, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Closures Covid-19 Boston, MA Health Healthcare Status Coronavirus Coronavirus Vaccine Moderna Therapeutics Source Type: news

World environment day 2020
By External SourceJun 3 2020 (IPS) My name is Emma, I’m 10 years old, and I live in Canada. I am sharing this video with you, today, because I learned at school that my future – the future of all children – will be determined by what we do together today. The life we lead – from the foods we eat, the air we breathe, the water we drink and the climate that makes our planet a livable place – comes from nature. If we do not do our part to help it, everything we have in our lives will be lost. We are at a point of “no return.” World Environment Day is the most important day for envi...
Source: IPS Inter Press Service - Health - June 3, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Biodiversity Environment Global Headlines Health Multimedia TerraViva United Nations Video Source Type: news

Valley marijuana operator reduces nationwide staff amid mounting losses
Amid quarterly losses, layoffs, divestiture of noncore assets and holding off on future acquisitions, the marijuana cultivation and dispensary firm is not blaming Covid-19 for its woes. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 21, 2020 Category: Biotechnology Authors: Angela Gonzales Source Type: news

Unusual Symptoms of Coronavirus: What We Know So Far
While most people are familiar with the hallmark symptoms of COVID-19 by now—cough, fever, muscle aches, headaches and difficulty breathing—a new crop of medical conditions are emerging from the more than 4 million confirmed cases of the disease around the world. These include skin rashes, diarrhea, kidney abnormalities and potentially life-threatening blood clots. It’s not unusual for viruses to directly infect and affect different tissues and organs in the body, but it is a bit unusual for a primarily respiratory virus like SARS-CoV-2, which is responsible for COVID-19, to have such a wide-ranging reach...
Source: TIME: Health - May 19, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Coronavirus Leads to Nosedive in Remittances in Latin America
Remittances now account for an important portion of GDP in Latin America and the Caribbean and support millions of families, so the drop in this source of income is shaking the economies of many countries and deepening poverty in the region. CREDIT: World BankBy Humberto MárquezCARACAS, May 18 2020 (IPS) Remittances that support millions of households in Latin America and the Caribbean have plunged as family members lose jobs and income in their host countries, with entire families sliding back into poverty, as a result of the COVID-19 health crisis and global economic recession. The region will receive a projected...
Source: IPS Inter Press Service - Health - May 18, 2020 Category: International Medicine & Public Health Authors: Humberto Marquez Tags: Development & Aid Economy & Trade Editors' Choice Featured Financial Crisis Headlines Health Human Rights Labour Latin America & the Caribbean Migration & Refugees Poverty & SDGs Regional Categories Coronavirus COVID-19 ECLAC Source Type: news

Mass General Brigham to lose $400M a month from Covid-19
Mass General Brigham expects to lose $400M per month due to the coronavirus shutdown. The health network's CFO said even in the first quarter, which included just the start of the pandemic, the system suffered a massive operating loss. It expects to lose $400 million a month for the coming quarter. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 15, 2020 Category: Biotechnology Authors: Jessica Bartlett Source Type: news

Sutter Health reports $1 billion first-quarter loss
The Sacramento-based health system has incurred heavy costs with its response to the Covid-19 pandemic. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 15, 2020 Category: Pharmaceuticals Authors: Felicia Alvarez Source Type: news

Sutter Health reports $1 billion first-quarter loss
The Sacramento-based health system has incurred heavy costs with its response to the Covid-19 pandemic. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 15, 2020 Category: Biotechnology Authors: Felicia Alvarez Source Type: news